What condition is primarily treated with Montelukast (Singulair)?

Montelukast, marketed under the brand name Singulair, is primarily used for the treatment of asthma. It is a leukotriene receptor antagonist, which means it works by blocking the action of leukotrienes—substances in the body that contribute to inflammation, bronchoconstriction, and mucus production in the airways. By inhibiting these effects, Montelukast helps to reduce the frequency of asthma attacks and improve lung function in patients with asthma.

It is particularly beneficial for patients who experience exercise-induced bronchoconstriction and those with allergic rhinitis, as it can help mitigate related respiratory symptoms. The drug is not indicated for the treatment of Chronic Obstructive Pulmonary Disease (COPD), diabetes, or cardiovascular diseases, as those conditions involve different pathophysiological processes that do not respond to leukotriene modulation in the same way asthma does. Thus, Montelukast's primary role is in managing asthma by addressing the underlying inflammation and airway constriction associated with this respiratory condition.